UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Epithelial–stromal interactions in the mouse and human mammary gland in vivo

Endocrine-related cancer, 2004-09, Vol.11 (3), p.437-458

2004

Volltextzugriff (PDF)

Cytoskeletal Microdifferentiation: A Mechanism for Organizing Morphological Plasticity in Dendrites

Proceedings of the National Academy of Sciences - PNAS, 2001-06, Vol.98 (13), p.7086-7092

2001

Volltextzugriff (PDF)

A Novel Method for Growing Human Breast Epithelium in Vivo Using Mouse and Human Mammary Fibroblasts

Endocrinology (Philadelphia), 2002-12, Vol.143 (12), p.4886-4896

2002

Volltextzugriff (PDF)

Modelling of Irrigation Return Flow in Unconfined Aquifer of Dharoi Command in Mehsana District of Gujarat, India

International journal of innovative technology and exploring engineering, 2021-10, Vol.10 (12), p.47-57

2021

Volltextzugriff (PDF)

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Cancer discovery, 2017-07, Vol.7 (7), p.704-715

2017

Volltextzugriff (PDF)

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Blood, 2021-11, Vol.138 (Supplement 1), p.301-301

2021

Volltextzugriff (PDF)

Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest

Cancer research (Chicago, Ill.), 2004, Vol.64 (1), p.423-428

2004

Volltextzugriff (PDF)

Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.LBA530-LBA530

2024

Volltextzugriff (PDF)

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Cancer, 2016-11, Vol.122 (22), p.3519-3528

2016

Volltextzugriff (PDF)

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Piezometric Assessment for Salinity in Multi Aquifer System in Dharoi Command Area, Gujarat

International journal of engineering and advanced technology, 2019-08, Vol.8 (6), p.945-951

2019

Volltextzugriff (PDF)

Multicenter, Open-Label, Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease (EBV+ PTLD) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R + C) (ALLELE)

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S22-S23

2022

Volltextzugriff (PDF)

23 - Multicenter, Open-Label, Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease (EBV+ PTLD) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R + C) (ALLELE)

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S22-S23

2022

Volltextzugriff (PDF)

Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2399-2399

2015

Volltextzugriff (PDF)

Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5513-5513

2014

Volltextzugriff (PDF)

Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT1-1-01-OT1-1-01

2015

Volltextzugriff (PDF)

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer

Molecular cancer therapeutics, 2015-07, Vol.14 (7_Supplement), p.A03-A03

2015

Volltextzugriff (PDF)

Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.915-915

2014

Volltextzugriff (PDF)

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.LB-64-LB-64

2013

Volltextzugriff (PDF)

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.PD5-2-PD5-2

2015

Volltextzugriff (PDF)

OPERATIONS: These 5 hedge fund execs made over $1B in '19

Money Management Executive, 2020-03, Vol.28 (3), p.1

2020

Volltextzugriff (PDF)

Identification of an epithelial-specific enhancer regulating ESX expression

Gene, 2006-02, Vol.367, p.118-125

2006

Volltextzugriff (PDF)

Activity-regulated, cytoskeleton-associated protein (Arc) is essential for visceral endoderm organization during early embryogenesis

Mechanisms of development, 2000-04, Vol.92 (2), p.207-215

2000

Volltextzugriff (PDF)

Model Application for salinity in Command Area

IOSR Journal of Mechanical and Civil Engineering, 2017-05, Vol.14 (3), p.1-11

2017

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Epithelial–stromal interactions in the mouse and human mammary gland in vivo

Cytoskeletal Microdifferentiation: A Mechanism for Organizing Morphological Plasticity in Dendrites

A Novel Method for Growing Human Breast Epithelium in Vivo Using Mouse and Human Mammary Fibroblasts

Modelling of Irrigation Return Flow in Unconfined Aquifer of Dharoi Command in Mehsana District of Gujarat, India

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest

Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Piezometric Assessment for Salinity in Multi Aquifer System in Dharoi Command Area, Gujarat

Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies

Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results

Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer

Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

OPERATIONS: These 5 hedge fund execs made over $1B in '19

Identification of an epithelial-specific enhancer regulating ESX expression

Activity-regulated, cytoskeleton-associated protein (Arc) is essential for visceral endoderm organization during early embryogenesis

Model Application for salinity in Command Area

Suchergebnisse filtern